TriPath/Digene
This article was originally published in The Gray Sheet
Executive Summary
TriPath will resubmit its withdrawn PMA supplement application to FDA "at the earliest possible date" for use of SurePath liquid-based Pap test specimen-collection medium samples with Digene's Hybrid Capture 2 (HC2) high-risk human papillomavirus (HPV) DNA test, the firm says. The withdrawal of the August 2004 application follows discussions with FDA that revealed "additional clinical information and analyses would be required," TriPath explains (1"The Gray Sheet" Aug. 30, 2004, In Brief). A Digene PMA supplement for the combination was rejected by FDA in 2002. TriPath reports it achieved profitability for the first time in 2004, earning $605,000 on sales of $68.5 mil., up 27%...
You may also be interested in...
TriPath Imaging Ramps Up Regulatory And Clinical Spending In 2006
TriPath Imaging will increase investment in its regulatory and clinical affairs programs by $6.5 mil.-$7 mil. in 2006 to support FDA approval of its breast cancer staging assay, SurePath molecular Pap test and FocalPoint GS imaging system
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.